"Being nominated and selected for the short list for `Company of the Year' at the European Mediscience Awards is an important recognition of the progress Cereno Scientific have made towards our vision in advancing truly innovative science in rare cardiovascular and pulmonary diseases with high unmet needs. This nomination reflects the dedication of our entire team, our trusted partners, and the strength of our shared mission to pioneer treatments that can enhance and extend life for patients with rare cardiovascular and pulmonary diseases," said Sten R. Sörensen, CEO at Cereno Scientific.

The European Mediscience Awards is the largest annual gathering of private and publicly listed healthcare, biotech and life science companies in the Europe recognizing achievements in the life sciences industry. Over 500 public and private UK and European life sciences companies and corporate advisers, analysts, fund managers, commentators and peers come together to celebrate achievement and recognize success. The categories for the 2025 Awards include Company of the Year, Chief Executive of the Year Award, Best Communication Award, Breakthrough of the Year Award, Best Technology Award, The Emerging Star Award, Mediscience Commentator of the Year Award, Capital Market Transaction of the Year Award and Most Significant Contribution to the Mediscience Sector Award. Previous winners of the Company of the Year Award, which Cereno Scientific has been nominated and shortlisted for, include Zealand Pharma, Novo Nordisk and Calliditas Therapeutics.

The European Mediscience Awards 2025 will take place on June 12, 2025, at the Hotel InterContinental in London, UK. For further information on the European Mediscience Awards, visit: http://www.mediscience-event.co.uk/.

For further information, please contact:

Tove Bergenholt, Head of IR & Communications

Email:  tove.bergenholt@cerenoscientific.com

Phone: +46 73- 236 62 46

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.

Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1's safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension.

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company's Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.